GlobeNewswire: Eloxx Pharmaceuticals Contains the last 10 of 140 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:04:43ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/13/2845650/0/en/Almirall-and-Eloxx-Pharmaceuticals-Enter-into-Exclusive-Agreement-to-license-ZKN-013-for-rare-dermatological-diseases.html?f=22&fvtc=4&fvtv=42099Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases2024-03-13T15:42:35Z<![CDATA[BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases. ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.]]>https://www.globenewswire.com/news-release/2023/11/13/2779493/0/en/Eloxx-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update2023-11-13T21:15:00Z<![CDATA[Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome]]>https://www.globenewswire.com/news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria2023-10-09T12:00:00Z<![CDATA[ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH]]>Podocyte Exact Morphology Procedure ResultsPodocyte Exact Morphology Procedure Resultshttps://www.globenewswire.com/news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules2023-09-19T12:00:00Z<![CDATA[WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/09/18/2744637/0/en/Eloxx-Pharmaceuticals-Reports-Independent-Confirmation-of-Positive-Biopsy-Results-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome2023-09-18T11:00:00Z<![CDATA[Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans]]>https://www.globenewswire.com/news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-0132023-09-07T13:00:52Z<![CDATA[Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations]]>https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update2023-08-14T12:30:00Z<![CDATA[Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02]]>https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome2023-08-14T12:00:00Z<![CDATA[All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02]]>https://www.globenewswire.com/news-release/2023/08/03/2718175/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement2023-08-03T13:26:09Z<![CDATA[WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the “Company”) to regain compliance with Listing Rule 5550(b)(2), which requires a listed company to have at least $35 million in market value of listed securities in order to qualify for continued listing on the Nasdaq Capital Market, until October 9, 2023, following a request for an extension and update submitted by the Company on July 27, 2023.]]>https://www.globenewswire.com/news-release/2023/07/10/2701816/0/en/Eloxx-Pharmaceuticals-Announces-Publication-Demonstrating-the-Power-of-its-TURBO-ZM-Platform-to-Target-the-Human-Ribosome-for-Therapeutic-Benefit.html?f=22&fvtc=4&fvtv=42099Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit2023-07-10T13:00:00Z<![CDATA[Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications]]>